Research on the Feasibility of Developing Computing Algorithms to Analyze EMR Data for Early Detection of ALS to be Presented at 32nd International Symposium on ALS/MND

Toronto, Canada
24 August 2021

Ensho Health today announced an Ensho-authored abstract has been accepted for poster discussion and presentations at the 32nd International Symposium on ALS/MND, to be held December 7-10.

"This research describes important early work in developing practical tools neurologists can use to improve early detection of amyotrophic lateral sclerosis in the community,” said Dr. Taha Bandukwala, Ensho Health Co-Founder and Chief Medical Officer. "We are grateful to Dr. Angela Genge, Dr. Amer Ghavanini, Mitsubishi-Tanabe Pharma, and EOCI Pharmacomm for their support and involvement."

Highlights include:

  • A heuristic algorithm deployed using the Apollo aEDC system by Ensho Health demonstrated a sensitivity of 100% in detecting amyotrophic lateral sclerosis ("ALS") and identified one individual in which ALS was clinically likely but not yet diagnosed
  • Further refinements to the algorithm are planned as are expanding its application to more pilot sites including to multidisciplinary centres for referral evaluation
  • Clinical algorithms can be applied to real-world electronic medical record data to aid in diagnosis of ALS in a neurological community practice

About Ensho Health

Ensho Health is a health technology company whose mission is to empower healthcare providers to do more with data. It realizes its mission with solutions that improve patient outcomes and facilitate groundbreaking research. It operates clinical data labs that make machine learning and other clinically validated algorithms for early detection and individualized treatment of rare and complex diseases accessible to physicians and their patients, and provide information extraction services for secondary use of data studies with its Apollo aEDC system.